Experimental Blood Test Spotted 92% of Precancerous Ovarian Lesions, Study Finds

Blood samples waiting to be tested in a laboratory. © Fumikas Sagisavas / Wikimedia Commons (CC0, cropped)
An experimental blood test may be able to find the earliest warning signs of ovarian cancer before a tumor forms, according to a study published this week in the journal Nature Medicine.
The test is not available to patients yet. The researchers say it still needs to be tested in larger groups of women over time.
Key points:
- The test looks for an RNA molecule called Tu-stroma, carried in tiny particles in the blood.
- In the group used to check the results, it found precancerous changes in 92.3% of women who had them.
- It correctly identified 98.2% of healthy women, according to Hoag, the California hospital that led the study.
Why Is Ovarian Cancer So Hard to Catch?
About 21,010 women in the U.S. will be diagnosed with ovarian cancer in 2026, and about 12,450 will die from it, the American Cancer Society estimates. There is no reliable screening test, so it is often found late, after it has spread.
The most common and deadliest type, high-grade serous carcinoma, is believed to start in the fallopian tubes. It begins as tiny abnormal patches called STIC. These cannot be seen on scans or found with current blood tests. Doctors usually find them only when the tubes are removed in surgery.
“Ovarian cancer does not begin the day we discover a tumour. It often begins much earlier, with microscopic changes in the fallopian tubes that we can’t see during routine screenings,” said Dr. Rajan Gogna, who led the study with Dr. Esha Madan at the Hoag Family Cancer Institute in Newport Beach, California.

What Did the Study Find?
The international team measured Tu-stroma in blood samples from 506 people. Levels were higher in women with STIC or with this type of ovarian cancer than in healthy women or women with harmless growths, the study says. It also performed better than CA-125, a blood marker that doctors use today.
When the researchers modeled a group of high-risk women, about 72% of positive results would be correct, while a negative result would be right nearly 100% of the time, Hoag said.
Who Could Benefit?
The researchers say the test could matter most for women at high risk, such as those with BRCA1 or BRCA2 gene mutations. Many of them face a hard choice about having their tubes and ovaries removed, sometimes before they have finished having children.
“For women at high risk, this could transform how we approach prevention,” Madan said.
What Are the Limits?
The study used blood samples that had been collected earlier. Hoag plans new studies that will follow women over time.
What you can do now: The NHS advises seeing a doctor if you often feel bloated, have pain in your tummy or pelvis, feel full quickly, or need to urinate more often. Tell your doctor if anyone in your family has had ovarian or breast cancer.
Sources:
- Nature Medicine: Blood-based RNA biomarker for the early detection of ovarian cancer
- Hoag via ecancer: Researchers discover ovarian cancer’s hidden warning, opening the possibility of detection years earlier
- American Cancer Society: Key statistics for ovarian cancer
- NHS: Ovarian cancer symptoms
- New York Post: New blood test could detect ovarian cancer before it develops
You might also want to read: Scientists Achieve Pancreatic Tumour Regression in New Study


